Enterprise Value
254.2M
Cash
300.3M
Avg Qtr Burn
-26.83M
Short % of Float
18.88%
Insider Ownership
6.09%
Institutional Own.
-
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
MAVYRET (Glecaprevir) Details HCV (Hepatitis C Virus) | Approved Quarterly sales | |
Zelicapavir /EDP-938 (N protein-inhibitor) Details Viral infection, Respiratory syncytial virus, Respiratory virus | Phase 2 Data readout | |
EDP-235 Details Viral infection, COVID-19 | Phase 2 Update | |
EDP-514 (HBV Core inhibitor) Details Hepatitis B | Phase 2 Initiation | |
EDP-323 Details Respiratory virus, Viral infection, Respiratory syncytial virus | Phase 2a Data readout | |
EDP-305 (FXR Agonist) Details Non-alcoholic steatohepatitis | Failed Discontinued | |
ENP-297 (FXR inhibitor) Details Non-alcoholic steatohepatitis | Failed Discontinued |